Progenity: Adi Mohanty

Adi Mohanty has been appointed as CEO of Progenity. He is also joining the firm's board of directors. Previously, he was the CEO of BioTime, and before that, a VP at Transkaryotic Therapies. Following the acquisition of Transkaryotic by Shire, he held several executive positions at Shire, including president of regenerative medicine. Mohanty holds an MS in chemical engineering from Clarkson University and an MBA from Saint Mary's College, California.